Navigation Links
Blocking toxic effects could make clot-buster safer
Date:1/23/2009

ATLANTA--Since the introduction of the life-saving clot-busting drug tPA more than a decade ago, evidence has been accumulating that tPA (tissue-type plasminogen activator) can be a double-edged sword for a brain affected by stroke. Although it remains the only FDA-approved treatment for acute stroke, tPA can also contribute to inflammation and brain cell damage.

Scientists at Emory University School of Medicine are testing strategies for blocking LRP1, a molecule that appears to transmit inflammation signals triggered by tPA. They have found that in mice, genetically removing LRP1 from certain brain cells called microglia softens tPA's impact on the brain.

The results, published online this week by the American Journal of Pathology, suggest that blocking tPA's toxic effects could make it safer and allow doctors to use it more often on patients experiencing a stroke.

"tPA is a protein released naturally by the body in response to a blood clot," says Manuel Yepes, MD, PhD, assistant professor of neurology at Emory University School of Medicine. "But it's clearly not just lysing the clot."

Doctors in community hospitals can often be reluctant to administer tPA to patients who appear to be having a stroke, Yepes says. One reason is that tPA has been shown to increase the risk of bleeding in the brain, he says.

Researchers have shown that tPA treatment increases the permeability of the blood-brain barrier, and that it can cross from the blood vessels into the brain tissue, generating inflammation. tPA targets cells called microglia, which are similar to white blood cells of the immune system, although they live in the brain.

"Our strategy was to show that by blocking LRP1, you can prevent the inflammatory response to tPA," Yepes says. "This can be done either genetically, by deleting LRP1, or perhaps pharmacologically."

Yepes and his colleagues are now testing a natural inhibitor of LRP1 called RAP in the laboratory. Co-treating or even pre-treating stroke patients with RAP might soften tPA's effects.

Researchers had previously been unable to examine the effects of deleting LRP1, a protein involved in transporting cholesterol and other molecules around the brain, because mice completely lacking the gene die in the womb.

Yepes and his colleagues collaborated with Dudley Strickland, PhD, professor of surgery and physiology at University of Maryland School of Medicine, who provided mice deficient in LRP1 in macrophages (white blood cells) and microglia only.

The authors showed that the genetically altered mice have half the number of activated microglia in the brain after treatment with tPA. In addition, the volume of brain tissue damaged by a simulated stroke was cut in half in the genetically altered mice.


'/>"/>

Contact: Jennifer Johnson
jrjohn9@emory.edu
404-727-5696
Emory University
Source:Eurekalert

Related medicine news :

1. Stopping ovarian cancer by blocking proteins coded by notorious gene
2. Blocking Oncogene Can Stop Spread of Ovarian Cancer
3. Blocking molecular pathway with whimsical name possible therapeutic target for pancreatic cancer
4. Pennsylvania Medical Society and AARP Criticize Senator Specter for Blocking Bill to Protect Access to Doctors and Improve Medicare
5. Blocking signaling protein prevents prostate cancer spread, Jefferson scientists find
6. Blocking the effect of inflammation-causing cells lowered prostate cancer cells invasion
7. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
8. Blocking Potent Oxidant Could Prevent Morphine Tolerance
9. Pre-emptive treatment helped curtail skin toxicity with panitumumab
10. DrScore.com Identifies Toxic Combination
11. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Hanna Boys Center ... will be the keynote speaker at its second Professional Networking Breakfast on March ... which develops comprehensive strategies to create and expand opportunities for boys and young ...
(Date:2/21/2017)... ... , ... As recently as 2015, rhinoplasty was one of the Top 5 ... Some patients want to make a change in the appearance of their nose while ... The team at usrhinoplasty.org is expanding its article database to better inform ...
(Date:2/21/2017)... ... 2017 , ... Ray Insurance Agencies, a Dallas area firm providing asset protection ... on a six month charity event aimed at raising local support and donations that ... of the deadliest diseases in America; more than 7.5 million people die from cancer ...
(Date:2/21/2017)... ... February 21, 2017 , ... American Veterinarian™, ... medicine, will be launching its first bi-monthly issue of 2017 in February. The ... practice management, and One Health. , In making the announcement, American Veterinarian™ ...
(Date:2/21/2017)... Michigan (PRWEB) , ... February 21, 2017 , ... ... to the United States during Black History Month (officially African American History ... to many fields of American society of a diverse race of people, but ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... their offering. ... research Uterine cancer Drugs Price Analysis and Strategies - 2016, provides drug ... The research answers the following questions: What are ... are they positioned in the Global Uterine cancer market? ...
(Date:2/20/2017)... Feb. 20, 2017   MedPlast, Inc. , ... industry, announced today that it has signed a ... Device Manufacturing Services business.   The acquisition broadens MedPlast,s ... a leading services provider to the world,s largest ... further expand the company,s capabilities in assembly and ...
Breaking Medicine Technology: